News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts. WEEKLY
Near-Infrared Assay and Content Uniformity of Tablets
Near-infrared (NIR) assay and content uniformity of tablets provide fast, accurate means of monitoring tablet production that are in step with FDA's process analytical technology initiative.The authors discuss the process for testing a newly released NIR tablet analyzer to determine instrument precision and accuracy using chlorpheniramine maleate tablets.The data show promising results that could relieve laboratory workload of high-performance liquid chromatography analysis and bring analysis closer to..
Partial least squares (PLS) regression was used to develop the prediction model. PLS uses principal component analysis and
is a variation of principal component regression (PCR). The correct number of principal components or factors was determined
by the Vision software supplied with the instrument by determining where the predicted residual error sum of squares (PRESS)
reaches a minimum (5).
Table II: Repeatability results for 0.1 mg and 0.5 mg tablets of chlorpheniramine maleate (CPM).
Figures 5 and 6 are plots of the PLS factor loadings and weights around the 1138-nm absorption band for CPM. The loadings
and weights appear spectra-like and are not noisy, indicating good modeling attributes for the factors chosen. Figure 7 is
a plot of the PRESS leading to a model with eight factors. The model chosen used only six of these factors, trading decreased
error for robustness (6). The PRESS for six factors was 0.0095. The resulting model had a multiple correlation coefficient
(R2 ) value of 0.9998 and a standard error of calibration (SEC) of 0.0119. The one-left-out cross-validation demonstrates good
predictability with a standard error of cross-validation of 0.0148.
Table III: Content uniformity test results for ten 0.1-mg chlorpheniramine maleate tablets.
Table I contains the model statistics for the CPM prediction equation. Table II is the repeatability results for five tablets
measured 10 times each of nominal 0.1 mg CPM and 10 tablets of 0.5 mg CPM. The same tablet placed in the same tray position
was scanned 10 times. Data for tablet tray position (number 1) are shown, and only the combined statistical results are shown
for the other four tablets from each dosage level. The average precision for the nominal 0.1-mg level was 0.0039. The precision
for the nominal 0.5-mg level was 0.0055. The bias was 0.0018 for the lower-level CPM and 0.0057 for the higher level. Table
III contains the results from scanning the ten 0.1 mg CPM tablets for content uniformity. Table IV contains the results from
scanning the ten 0.5-mg CPM tablets for content uniformity. The Vision software has a convenient routine analysis method for
calculating content uniformity automatically. Figures 8 and 9 are X control charts for the 0.1-mg and 0.5-mg CPM content uniformity
tests. These charts are for SPC, plotting target label claim and ±15% control limits. The HPLC results showed that some of
the nominal 0.5-mg CPM tablets were as high as 0.53 mg CPM.
Table IV: Content uniformity test results for ten 0.5-mg chlorpheniramine maleate (CPM) tablets.
Om Anand is a graduate student in the Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN.
Articles by Om Anand
Maria Gerald Rajan
Maria Gerald Rajan is a gradutate student in the Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN.
Articles by Maria Gerald Rajan
Namrata R. Trivedi
Namrata R. Trivedi is a gradutate student in the Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN.
Articles by Namrata R. Trivedi
Wen Qu
Wen Qu is a graduate student in the Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN.
Articles by Wen Qu
Yingxu Peng
Yingxu Peng, PhD, is a postdoctorate fellow in the Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN.
Articles by Yingxu Peng
Yichun Sun
Yichun Sun, PhD, is a postdoctorate fellow in the Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN.
Articles by Yichun Sun
Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
21%
To all process for new products only
11%
To select process for new products only
25%
To select processes for both new and legacy products
